VoSpire ER® (Albuterol Sulfate) Extended-Release Tablets are indicated for the relief of bronchospasm in adults and children 6 years of age and older with reversible obstructive airway disease
Patients 6 to 12 years of age: 4 mg every 12 hours
Patients over 12 years of age: 8 mg every 12 hours*
*In some patients 12 years of age and older, 4 mg every 12 hours may be sufficient.
One small, extended-release, coated tablet provides up to 12 hours duration of action
Extended-release formulation allows for twice-daily dosing
4 mg and 8 mg tablets allow for individualized dosing
Option for bronchospasm treatment in conjunction with 1st line reversible obstructive airway
The appropriateness of VoSpire ER® therapy should be determined by the physician based on individual patient needs
Option for patients who simply prefer oral medications
VoSpire ER® (Albuterol Sulfate) Extended-Release Tablets must be swallowed whole with
the aid of liquids. DO NOT CRUSH OR CHEW THESE TABLETS
Important Safety Information
VoSpire ER® Tablets should be used with caution in patients with cardiovascular disorders (especially coronary insufficiency, cardiac arrhythmias, and hypertension), convulsive disorders, hyperthyroidism, or diabetes. Do not exceed the recommended dose. Albuterol extended-release tablets can produce paradoxical bronchospasm, which may be life threatening. If paradoxical bronchospasm occurs, albuterol extended-release tablets should be discontinued immediately and alternative therapy instituted. Potential drug interactions can occur with beta-blockers, diuretics, digoxin, or monoamine oxidase inhibitors and tricyclic antidepressants. Adverse reactions are generally transient. The most common adverse reactions reported in clinical trials of adult patients were: tremor, headache, nervousness, and nausea and vomiting. The safety and effectiveness of albuterol extended-release tablets have been established in pediatric patients 6 years of age and older via evidence from adequate and well-controlled studies of albuterol extended-release tablets in adults; the established safety and effectiveness of immediate release albuterol tablets in pediatric patients 6 years of age and older; and clinical trials that support the safety of albuterol extended-release tablets in pediatric patients over 6 years of age. Please see Brief Summary on the back of this
page for important considerations regarding albuterol.
VoSpire ER® is a registered trademark of DAVA Pharmaceuticals, Inc.
For more information on VoSpire ER® Tablets please visit www.vospireer.com or www.davapharma.com
DAVA Headquarters: Parker Plaza, 400 Kelby Street, 10th Floor, Fort Lee, New Jersey 07024. Toll free: (866) 947-DAVA (3282). Telephone: (201) 947-7442. Fax: (201) 947-7964
Biofrontera Pharmaceuticals AG Abkommen zwischen Biofrontera Pharmaceuticals und JanssenPharmaceutica zur Erforschung der Modulationsfähigkeit nikotinischerRezeptoren bei der Alzheimer-Behandlung27.08.2001 - 09:03 Uhr, Biofrontera Pharmaceuticals AG Leverkusen (ots) - Die Unternehmen Janssen Pharmaceutica NV undBiofronteraPharmaceuticals AG geben heute bekannt, dass sie in einemgemeinsamem Fo
Medicaid and North Carolina Health Choice Updates November 2011 CSC Updates and Information o The enrollment requirement for Physician Assistants (PA) and Nurse Practitioners (NP) is being delayed until further notice from DMA. A State Plan Amendment has been submitted to CMS to allow the direct enrollment of PAs. NPs are already allowed to direct enroll with Medicaid. The Med